Unregistered Sales of Equity Securities. The disclosure in

Entry into a Material Definitive Agreement. On September 24, 2026, Creative Medical Technology Holdings, Inc. (the “Company”) entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Creative Acquisition Corp. (“CAC”), pursuant to which the Company purchased 4,000,000 shares of common stock of BioDefense, Inc. (“BioDefense”) from CAC for an aggregate purchase price consisting of $200,000 in cash and 1,000,000 shares of the Company’s common stock. After giving effect to the tran…

Unregistered Sales of Equity Securities. The disclosure in

Entry into a Material Definitive Agreement. On June 30, 2026, Creative Medical Technology Holdings, Inc. (the “Company”) entered into warrant exercise inducement offer letters (the “Inducement Letters”) with the holders (the “Holders”) of warrants to purchase an aggregate of 2,790,340 shares of the Company’s common stock originally issued on October 29, 2025 (collectively, the “Existing Warrants”), pursuant to which the Holders agreed to exercise the Existing Warrants at an exercise price of…

The filing is about a bonus payment, not a management change.

The filing pertains to the approval of bonuses for executives, not a management change.

Entry into a Material Definitive Agreement. On October 29, 2025, Creative Medical Technology Holdings, Inc. (the “Company”) entered into warrant exercise inducement offer letters (the “Inducement Letters”) with the holders (the “Holders”) of warrants to purchase an aggregate of 1,116,136 shares of the Company’s common stock originally issued on March 6, 2025 (collectively, the “Existing Warrants”), pursuant to which the Holders agreed to exercise the Existing Warrants at their current exercis…

Unregistered Sales of Equity Securities. The disclosure in

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 4, 2025, Creative Medical Technology Holdings, Inc. (the “Company”) adopted a Clawback Policy (the “Policy”) pursuant to Listing Rule 5608(b)(1) of The Nasdaq Stock Market LLC (“Nasdaq”), and filed the Policy with the Securities and Exchange Commission as an exhibit to its Amended Annual Report on Form 10-K. Although the Clawback Policy has been adopted with retroactive effect to Dece…

The filing details the approval of bonuses for certain officers, which is a compensatory arrangement and not a management change.

Entry into a Material Definitive Agreement. On March 6, 2025, Creative Medical Technology Holdings, Inc. (the “Company”) entered into warrant exercise inducement offer letters (the “Inducement Letters”) with the holders (the “Holders”) of warrants to purchase an aggregate of 837,104 shares of the Company’s common stock originally issued on October 23, 2024 (collectively, the “Existing Warrants”), pursuant to which the Holders agreed to exercise the Existing Warrants at their current exercise…

Unregistered Sales of Equity Securities. The disclosure in

Entry into a Material Definitive Agreement. On October 22, 2024, Creative Medical Technology Holdings, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Investors”), pursuant to which the Company agreed to sell and issue in a registered direct offering (the “Registered Offering”) 418,552 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at a purchase price p…

Unregistered Sales of Equity Securities. The information set forth under

Entry into a Material Definitive Agreement. On May 14, 2024, Creative Medical Technology Holdings, Inc. (the “Company”) entered into a Securities Purchase Agreement with Timothy Warbington, the Company’s Chief Executive Officer, pursuant to which Mr. Warbington purchased one share of the Company’s newly designated Series B Preferred Stock (the “Series B Preferred Stock”), for a purchase price of $100.00. The Series B Preferred Stock has the rights, preferences, privileges, qualifications, lim…

Material Modification to Rights of Security Holders. The information set forth under

Material Modification to Rights of Security Holders.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 8, 2022, Creative Medical Technology Holdings, Inc. (the “Company”) received a letter from The Nasdaq Stock Market stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price of the Company’s common stock was below $1.00 per share for 30 consecutive business days. The notice has no immediate impact on the Company’s listing. Pursuant…

Unregistered Sales of Equity Securities. The information set forth under

Entry into a Material Definitive Agreement. On May 3, 2022, Creative Medical Technology Holdings, Inc. (the “Company”) completed the sale of (i) 2,991,669 shares of the Company’s common stock (the “Common Stock”), and pre-funded warrants to purchase 4,563,887 shares of Common Stock (the “Pre-Funded Warrants”), and (ii) accompanying warrants to purchase 15,111,112 shares of Common Stock (the “Common Warrants”), at a combined offering price of $2.25 per share of Common Stock/Pre-Funded Warrant…

Entry into a Material Definitive Agreement. On May 3, 2022, Creative Medical Technology Holdings, Inc. (the “Company”) completed the sale of (i) 2,991,669 shares of the Company’s common stock (the “Common Stock”), and pre-funded warrants to purchase 4,563,887 shares of Common Stock (the “Pre-Funded Warrants”), and (ii) accompanying warrants to purchase 15,111,112 shares of Common Stock (the “Common Warrants”), at a combined offering price of $2.25 per share of Common Stock/Pre-Funded Warrant…

Unregistered Sales of Equity Securities. The information set forth under

CEO — Timothy Warbington: The filing discloses the execution of new employment agreements and compensation terms for existing executives, not a change in management status or departure.

Entry into a Material Definitive Agreement. On December 7, 2021, Creative Medical Technology Holdings, Inc. (the “Company”) sold an aggregate of 3,875,000 shares of the Company’s common stock (“Common Stock”), and accompanying warrants to purchase 3,875,000 shares of Common Stock at an exercise price of $4.13 per share (“Warrants”), at a combined public offering price to the public of $4.13 per share of Common Stock and related Warrant (the “Offering”), pursuant to an Underwriting Agreement,…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. In connection with the Offering, the Company’s Common Stock began trading on The NASDAQ Capital Market on December 3, 2021 under the symbol “CELZ”. The Common Stock was previously quoted on the Pink Market maintained by OTC Markets Group under the symbol “CELZ.”